{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:26:14Z","timestamp":1788881174356,"version":"build-2803163510"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to describe bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICIs) reported in the United States Food and Drug Administration adverse event reporting system (FAERS). We obtained reports of ICI\u2010associated BP from the first quarter of 2011 to the first quarter of 2024 in the FAERS database. The reporting odds ratio (ROR) method of the disproportionality analysis was performed to assess the potential risk for ICI\u2010associated BP. We also described the clinical characteristics of ICI\u2010associated BP and evaluated the time to onset (TTO) of BP developed after treatment with ICIs. Eight hundred and six cases of ICI\u2010associated BP were gathered, in which 56.58% of the patients were aged 65\u2009years or older. The majority of patients were male, accounting for 68.49% of all cases. The prevalent potential cancer type was skin cancer (31.64%). The results of the disproportionality analysis showed that males (ROR\u2009=\u20092.10 [1.78\u20132.49]), patients aged 65 or older (ROR\u2009=\u20092.13 [1.79\u20132.55]), and patients with skin cancer (ROR\u2009=\u20092.08 [1.80\u20132.43]) were more likely to develop ICI\u2010associated BP. In comparison to cytotoxic T\u2010lymphocyte\u2010associated antigen 4 inhibitor and programmed cell death ligand 1 inhibitor, programmed cell death 1 inhibitor\u2010associated BP has a higher risk of development (ROR\u2009=\u200924.45 [22.52\u201326.56]). ICI\u2010associated BP had a median TTO of 204\u2009days (interquartile range 57\u2013426\u2009days). ICI\u2010associated BP is a rare but important immune\u2010related adverse event. Our study provided helpful information to help medical professionals further understand ICI\u2010associated BP.<\/jats:p>","DOI":"10.1111\/1346-8138.17517","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T07:20:38Z","timestamp":1729927238000},"page":"309-316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immune checkpoint inhibitor\u2010associated bullous pemphigoid: A\u00a0retrospective and real\u2010world study based on the United States Food and Drug Administration adverse event reporting system"],"prefix":"10.1111","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0754-3373","authenticated-orcid":false,"given":"Haowen","family":"Tan","sequence":"first","affiliation":[{"name":"Office of Good Clinical Practice Wuzhou Red Cross Hospital  Wuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubi","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Adverse Drug Reaction Monitoring of Mianyang  Mianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Office of Good Clinical Practice Wuzhou Red Cross Hospital  Wuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Ou","sequence":"additional","affiliation":[{"name":"Office of Good Clinical Practice Wuzhou Red Cross Hospital  Wuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[{"name":"Information Technology Center, Open University  Ziyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xida","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Central Hospital  Mianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.023"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.03.034"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16654"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3740"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13984"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215451"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1619693"},{"key":"e_1_2_11_12_1","unstructured":"21 CFR \u00a7 600.80\u2014Postmarketing reporting of adverse experiences. [cited 2024 July 5].https:\/\/www.govinfo.gov\/app\/details\/CFR\u20102023\u2010title21\u2010vol7\/CFR\u20102023\u2010title21\u2010vol7\u2010sec600\u201080\/context"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15361"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01397-w"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30090566"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2959"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14043"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S73389"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0354"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1624"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10972"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae172"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-012-0981-9"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.16.8569"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3335"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59111950"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2000.tb02141.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2002.01037.x"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2022.2034842"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00866-z"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.045"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18220"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T17:30:03Z","timestamp":1747675803000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/1346-8138.17517"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17517","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"2024-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}